Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 511 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Graft Versus Host Disease Oral Clear all
Completed Phase 2 Interventional Results available

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction

NCT02992288
View directory record Official record
Conditions
Heart Failure
Interventions
Neladenoson bialanate (BAY1067197), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Naples, Florida • Detroit, Michigan • Jackson, Mississippi + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional Results available

Single Dose Pravastatin Pharmacokinetics in Pediatric Peritoneal Dialysis Patients

NCT00571194
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
pravastatin
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
12 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

NCT03087058
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer
Drug
Lead sponsor
Vifor Pharma, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Palo Alto, California • Kansas City, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

CEP-701 for PH-negative Myelofibrosis

NCT00494585
View directory record Official record
Conditions
Leukemia, Myelofibrosis
Interventions
CEP-701
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia

NCT00003735
View directory record Official record
Conditions
Leukemia
Interventions
topotecan hydrochloride
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
35
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 4 Interventional

Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control

NCT00744250
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Cystic Fibrosis
Interventions
Pancrelipase
Drug
Lead sponsor
Digestive Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212
View directory record Official record
Conditions
Cholestatic Pruritus
Interventions
CR845 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Coronado, California • Rialto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Oral Dexamethasone Doses in Asthma Exacerbation

NCT00942201
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
Dexamethasone
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

NCT00010283
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 14, 2026, 5:45 AM EDT
Active, not recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

NCT05593237
View directory record Official record
Conditions
Chronic Neuropathic Pain, Post-Stroke Pain, Trigeminal Neuralgia, Nerve Injury, Spinal Cord Injuries, Pain, Postoperative, Complex Regional Pain Syndromes, Post-herpetic Neuralgia, Nerve Root Avulsion
Interventions
High Frequency rTMS, Low Frequency rTMS
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease

NCT00686855
View directory record Official record
Conditions
Oral Chronic Graft-versus-host Disease
Interventions
Tacrolimus, Dexamethasone
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
4 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Silymarin for Chronic Liver Diseases

NCT00389376
View directory record Official record
Conditions
Hepatitis C, Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Silymarin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2008 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

NCT01419691
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, Leukemia, Prolymphocytic
Interventions
auranofin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema

NCT00874497
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
tetomilast, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Torrance, California • Kissimmee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children

NCT03815019
View directory record Official record
Conditions
Feeding Behavior, Feeding Disorder of Infancy or Early Childhood
Interventions
Megestrol Acetate, iKanEat Behavioral Intervention
Drug · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
9 Months to 108 Months
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
8
States / cities
San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 14, 2026, 5:45 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant

NCT04020458
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Interventions
dental intervention
Procedure
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

NCT01976104
View directory record Official record
Conditions
Thrombocytopenia Associated With Liver Disease
Interventions
avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional

ADX-629 Therapy for Sjogren-Larsson Syndrome

NCT05443685
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-629
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501
View directory record Official record
Conditions
Hematologic Cancer
Interventions
ABBV-101, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 14, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

NCT00299156
View directory record Official record
Conditions
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 14, 2026, 5:45 AM EDT
Withdrawn No phase listed Observational

Oral Steroid Treatment for Chronic Rhinosinusitis

NCT01255683
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
oral corticosteroid taper
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 14, 2026, 5:45 AM EDT